Frontier mental health research: psychedelics & drug studies

Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.

2 papers

A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol

Cinzia Citti, Pasquale Linciano, Fabiana Russo, Livio Luongo, Monica Iannotta, Sabatino Maione, et al.
Scientific Reports Summary & key facts 2019 200 citations

Researchers isolated a new natural cannabis compound called Δ9-tetrahydrocannabiphorol (Δ9-THCP) and its CBD counterpart (CBDP). In lab tests, Δ9-THCP bound very strongly to the human CB1 receptor (Ki = 1.2 nM) and caused THC-like effects in mice (less movement, pain relief, catalepsy, and lower body temperature). The authors say Δ9-THCP…

Biochemical Analysis and Sensing Techniques Cannabis and Cannabinoid Research GABA and Rice Research

Attitudes of European psychiatrists on psychedelics: a cross-sectional survey study

Marija Franka Žuljević, Darko Hren, Dawid Storman, Mariano Kaliterna, Darko Duplančić
Scientific Reports Summary & key facts 2024 7 citations

The study surveyed 419 psychiatrists working in 33 European countries about their knowledge and attitudes toward psychedelics and psychedelic-assisted psychotherapy (PAP). Overall, psychiatrists showed general openness to psychedelics and PAP but also notable concern about risks. Younger age, being male, higher knowledge, identifying as spiritual, past personal use of psychedelics,…

Psychedelics and Drug Studies
Summaries and links are for general information and education only. They are not a substitute for reading the original publication or for professional medical, legal, or other advice. Always refer to the linked source for the full study.